Older adults with subclinical hypothyroidism who were prescribed levothyroxine had lower risk for cardiovascular events than those not prescribed the therapy, according to findings published in ...
Across hospitals and health systems, stroke care sits at the intersection of several pressures leaders know well: rising acuity, uneven access to specialty care, workforce constraints and growing ...
Non-inferiority trials are a valuable type of clinical trial to evaluate new treatments that might have differing benefits. Such trials are increasingly used, but have methodological challenges in ...
The growth of the acute ischemic stroke market is expected to be driven primarily by increased awareness of symptoms, advances in acute stroke care, and a robust pipeline of potential candidates such ...
KalVista Pharmaceuticals, Inc. today announced new data from its sebetralstat clinical trial program presented at the 2026 American Academy of Allergy, Asthma & Immunology (AAAAI) Annual Meeting and ...
Cardiovascular disease remains the leading cause of mortality worldwide, necessitating deeper insights into its molecular underpinnings beyond genetic predisposition. Epigenetic modifications, ...
Background Cardiovascular disease (CVD) is the leading cause of mortality worldwide, while depression is highly prevalent in this patient population and has long been regarded as an independent risk ...
Myocardial infarction in children is an infrequent phenomenon. Here, we are reporting a case of paediatric systemic lupus erythematosus with autoimmune haemolytic anaemia and anti-phospholipid ...
Introduction Hypertension programmes have expanded substantially in low-income and middle-income countries, yet treatment and control rates remain insufficient. Programme scale-up may lead to ...
Discover how modern cardiovascular services protect your heart. Learn about expert cardiology care teams and preventative ...
More than a third of patients were menopausal, and one in seven were men. Experts say awareness is key, but so too are protocols.
New presentations for tildrakizumab-asmn explore real-world use in U.S. patients using Medicare New data specific to patients with skin of color expands ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results